MCY-M11

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMCY-M11

Drug Alias NameMCY-M11

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionAnti-Mesothelin

TargetsMesothelin

Therapy Area/IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsAdenocarcinoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMaxcyte Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMaxcyte Inc

Active IndicationsN/A

Inactive IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsAdenocarcinoma +[4]

Other Information

ATC CodeN/A